Phaseline

Companies › Alkeus Pharmaceuticals

Alkeus Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 3; Ophthalmology; next expected readout Jun 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ALK-001
Deuterated vitamin A analog that slows production of lipofuscin and related retinoid bypro
LRATPhase 3Stargardt DiseaseJun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT02402660ALK-001Phase 2Stargardt DiseaseOphthalmologyJun 2028
NCT04239625ALK-001Phase 2Stargardt DiseaseOphthalmologyDec 2028
NCT07419334ALK-001Phase 3Stargardt DiseaseOphthalmologyOct 2029

Targets

LRAT (1)

Companies with the same targets

–

Companies built like this

ReGenTree Ocus Innovation Ireland Ocumension Therapeutics (Suzhou) Laboratorios Sophia S.A de C.V. Cloudbreak Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.